Unbalanced reporting of benefits and harms in abstracts on rofecoxib

被引:0
作者
Anders W. Jørgensen
Karsten Juhl Jørgensen
Peter C. Gøtzsche
机构
[1] The Nordic Cochrane Centre,
来源
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词
Rofecoxib; Cyclooxygenase-2 inhibitors; Abstracts; Bias; Thrombosis; Gastrointestinal bleeding;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:341 / 347
页数:6
相关论文
共 193 条
[21]  
Wager E(2008)Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation JAMA 299 1800-546
[22]  
Middleton P(2008)The ADVANTAGE seeding trial: a review of internal documents Ann Intern Med 149 251-962
[23]  
Altman DG(2003)Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial Ann Intern Med 139 539-719
[24]  
Schulz KF(2009)Pfizer settles largest ever fraud suit for off-label promotion Nat Biotechnol 27 961-56
[25]  
Krumholz HM(2003)Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis J Rheumatol 30 714-237
[26]  
Ross JS(1989)Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis Controlled Clin Trials 10 31-592
[27]  
Presler AH(1996)Influences on the quality of published drug studies Int J Tech Assess Health Care 12 209-1173
[28]  
Egilman DS(2002)Design and reporting modifications in industry-sponsored comparative psychopharmacology trials J Nerv Ment Dis 190 583-1288
[29]  
Knijff-Dutmer EAJ(2003)Evidence b(i)ased medicine -selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications BMJ 326 1171-2635
[30]  
Martens A(2007)Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others PLoS Med 4 e184-2586